A first-in-human trial in patients with refractory castration-resistant metastatic prostate cancer has been initiated with a prostate-specific membrane antigen (PSMA)-specific CAR incorporating this receptor (NCT04227275) (74). Here, FOLH1 is linked to metastatic prostate carcinoma.